For individuals with symptomatic disease demanding therapy, ibrutinib is commonly advisable determined by four phase III randomized clinical trials evaluating ibrutinib with chlorambucil monotherapy106 and other frequently employed CIT combos, namely FCR, bendamustine plus rituximab and chlorambucil additionally obinutuzumab (ClbO).107–109 Ibruti